NVG, LLC for ALEXION PHARMACEUTICALS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 22, 2018 | $50,000 | Replaced |
| 4th Quarter - Amendment | Oct 10, 2018 | $60,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Intellectual property and potential changes to the patent system, generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA LARUE | — |
Medicare/Medicaid MMM
Orphan drug payments under Medicare Part A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| ANDREA LARUE | — |
Health Issues HCR
FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues; H.R. 1231/S. 456 - Research to Accelerate Cures and Equity for Children Act; Orphan Drug tax provisions in H.R. 1.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| PATRICIA GRIFFIN | — |
| ANDREA LARUE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.